A Randomized, Double-blind, Sponsor-open, Placebo-controlled, Single Intravenous Or Subcutaneous Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-06741086 In Healthy Subjects And An Open-label Evaluation In Healthy Japanese Subjects

Trial Profile

A Randomized, Double-blind, Sponsor-open, Placebo-controlled, Single Intravenous Or Subcutaneous Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-06741086 In Healthy Subjects And An Open-label Evaluation In Healthy Japanese Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Aug 2016

At a glance

  • Drugs PF 6741086 (Primary) ; PF 6741086 (Primary)
  • Indications Haemophilia
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 10 Aug 2016 Status changed from recruiting to completed.
    • 26 May 2016 Planned End Date changed from 1 Aug 2016 to 1 Jul 2016.
    • 26 May 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Jul 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top